Drugs / Sinopharm inactivated COVID-19 vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT05308602 Comparator | Apr → Aug 2022 | COVID-19 | Sinocelltech Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05239806 Comparator | Apr → Aug 2022 | COVID-19 | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05238454 Comparator | Mar → Jul 2022 | COVID-19 | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05323461 Comparator | May → Oct 2022 | COVID-19 | Sinocelltech Ltd. | Unknown | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sinopharm inactivated COVID-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05238454 ↗ |
| Known as | BBBIP-CorV | “Sinopharm's inactivated SARS-CoV-2 vaccine (BBBIP-CorV)” PMID 37731938 ↗ Sep 2023 |
| Modality | Vaccine | “Sinopharm inactivated COVID-19 vaccine” NCT05238454 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT05238454 ↗ |